Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei HII01
- Development stage
- Unknown
- Lead developer
- Chiang Mai University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus paracasei HII01 is a specific probiotic strain of bacteria originally isolated from the fermentation of northern Thai pickle. [2] It is being investigated for a range of therapeutic benefits. Clinical and preclinical studies have shown that L. paracasei HII01 can improve metabolic conditions such as obesity, insulin resistance, and type 2 diabetes. [2, 13] Its primary mechanism of action involves modulating the gut microbiota, which leads to a reduction in gut inflammation, decreased intestinal permeability (leaky gut), and lower systemic endotoxemia (LPS levels). [2, 7] This modulation has been linked to improved glycemic control and a decrease in inflammatory markers like TNF-α and IL-6. [2, 13] Beyond metabolic diseases, research also suggests potential benefits in promoting healthy aging and providing neuroprotection, as demonstrated in C. elegans models where it extended lifespan and protected against amyloid-beta toxicity. [10, 14] It has been studied both as a standalone probiotic and as part of synbiotic formulations.
- Other names
- L. paracasei HII01
Beyond the preview
Go deeper on Lactobacillus paracasei HII01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei HII01.